- Home
- BEEP vs IMA Comparison
BEEP vs IMA Comparison
Compare BEEP & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEEP | IMA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 66.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BEEP | IMA |
|---|---|---|
| Price | $1.59 | $5.94 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $6.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 47.7K | 13.1K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,075,000.00 | N/A |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $22.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $3.94 |
| 52 Week High | $4.67 | $17.50 |
Technical Indicators
Market Signals| Indicator | BEEP | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 33.06 | 55.93 |
| Support Level | N/A | $5.86 |
| Resistance Level | $2.34 | $6.06 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 6.40 | 70.42 |
Price Performance
Historical ComparisonAbout BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.